PT3108895T - Tratamento de doenças de armazenanto de glicogénio tipo ii - Google Patents

Tratamento de doenças de armazenanto de glicogénio tipo ii

Info

Publication number
PT3108895T
PT3108895T PT16178390T PT16178390T PT3108895T PT 3108895 T PT3108895 T PT 3108895T PT 16178390 T PT16178390 T PT 16178390T PT 16178390 T PT16178390 T PT 16178390T PT 3108895 T PT3108895 T PT 3108895T
Authority
PT
Portugal
Prior art keywords
storage disease
disease type
treatment
glycogen storage
glycogen
Prior art date
Application number
PT16178390T
Other languages
English (en)
Portuguese (pt)
Inventor
Chen Yuan-Tsong
Original Assignee
Univ Duke
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22818451&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT3108895(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Duke filed Critical Univ Duke
Publication of PT3108895T publication Critical patent/PT3108895T/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/0102—Alpha-glucosidase (3.2.1.20)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PT16178390T 2000-07-18 2001-07-10 Tratamento de doenças de armazenanto de glicogénio tipo ii PT3108895T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US21923700P 2000-07-18 2000-07-18

Publications (1)

Publication Number Publication Date
PT3108895T true PT3108895T (pt) 2018-12-18

Family

ID=22818451

Family Applications (5)

Application Number Title Priority Date Filing Date
PT16178390T PT3108895T (pt) 2000-07-18 2001-07-10 Tratamento de doenças de armazenanto de glicogénio tipo ii
PT181947714T PT3449934T (pt) 2000-07-18 2001-07-10 Tratamento de doença de armazenanto de glicogénio tipo ii
PT01951000T PT1301201E (pt) 2000-07-18 2001-07-10 Tratamento da doença de armazenamento de glicogénio tipo ii
PT70010913T PT1782825E (pt) 2000-07-18 2001-07-10 Tratamento de doenças de armazenanto de glicogénio tipo ii
PT141678821T PT2767291T (pt) 2000-07-18 2001-07-10 Tratamento de doenças de armazenanto de glicogénio tipo ii

Family Applications After (4)

Application Number Title Priority Date Filing Date
PT181947714T PT3449934T (pt) 2000-07-18 2001-07-10 Tratamento de doença de armazenanto de glicogénio tipo ii
PT01951000T PT1301201E (pt) 2000-07-18 2001-07-10 Tratamento da doença de armazenamento de glicogénio tipo ii
PT70010913T PT1782825E (pt) 2000-07-18 2001-07-10 Tratamento de doenças de armazenanto de glicogénio tipo ii
PT141678821T PT2767291T (pt) 2000-07-18 2001-07-10 Tratamento de doenças de armazenanto de glicogénio tipo ii

Country Status (17)

Country Link
US (10) US7056712B2 (enExample)
EP (4) EP3449934B1 (enExample)
JP (10) JP5113312B2 (enExample)
AT (1) ATE355075T1 (enExample)
AU (3) AU7194101A (enExample)
BR (1) BR0113006A (enExample)
CA (1) CA2416492C (enExample)
CY (2) CY1120977T1 (enExample)
DE (1) DE60126947T2 (enExample)
DK (5) DK1782825T3 (enExample)
ES (5) ES2599401T3 (enExample)
LT (3) LT2767291T (enExample)
MX (1) MXPA03000474A (enExample)
PT (5) PT3108895T (enExample)
SI (3) SI3108895T1 (enExample)
TW (1) TWI280882B (enExample)
WO (1) WO2002005841A1 (enExample)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7056712B2 (en) * 2000-07-18 2006-06-06 Duke University Treatment of glycogen storage disease type II
US7629309B2 (en) * 2002-05-29 2009-12-08 Zystor Therapeutics, Inc. Targeted therapeutic proteins
US20040005309A1 (en) * 2002-05-29 2004-01-08 Symbiontics, Inc. Targeted therapeutic proteins
EP1436316B1 (en) * 2001-04-30 2008-01-23 ZyStor Therapeutics , Inc. Subcellular targeting of therapeutic proteins
US7560424B2 (en) 2001-04-30 2009-07-14 Zystor Therapeutics, Inc. Targeted therapeutic proteins
US6981964B2 (en) 2001-05-22 2006-01-03 Boston Scientific Scimed, Inc. Draining bodily fluids with a stent
US20030072761A1 (en) * 2001-10-16 2003-04-17 Lebowitz Jonathan Methods and compositions for targeting proteins across the blood brain barrier
US6733536B1 (en) 2002-10-22 2004-05-11 Scimed Life Systems Male urethral stent device
PT1587923E (pt) 2003-01-22 2011-12-07 Univ Duke Construções melhoradas para a expressão de polipéptidos lisossomais
US7442372B2 (en) 2003-08-29 2008-10-28 Biomarin Pharmaceutical Inc. Delivery of therapeutic compounds to the brain and other tissues
US7129049B2 (en) * 2003-12-22 2006-10-31 Regents Of The University Of Minnesota Method of detecting equine glycogen storage disease IV
DE602005020745D1 (de) * 2004-02-10 2010-06-02 Zystor Therapeutics Inc Saure alpha-glukosidase und fragmente davon
US20050208090A1 (en) * 2004-03-18 2005-09-22 Medtronic, Inc. Methods and systems for treatment of neurological diseases of the central nervous system
EP1773401B1 (en) * 2004-06-21 2013-01-02 Medtronic, Inc. Medical systems and methods for delivering compositions to cells
AU2007322123A1 (en) * 2006-11-13 2008-05-29 Biomarin Pharmaceutical Inc. Methods for treating Pompe disease
WO2009075815A1 (en) 2007-12-07 2009-06-18 Duke University Immunomodulating gene therapy
WO2009137721A2 (en) 2008-05-07 2009-11-12 Zystor Therapeutics, Inc. Lysosomal targeting peptides and uses thereof
US9050333B2 (en) 2008-07-08 2015-06-09 Duke University Method of treating glycogen storage disease type III with human acid α-glucosidase
US8785168B2 (en) 2009-06-17 2014-07-22 Biomarin Pharmaceutical Inc. Formulations for lysosomal enzymes
US8809282B2 (en) 2010-05-06 2014-08-19 Duke University Method of reducing titers of antibodies specific for a therapeutic agent
JP2016514096A (ja) 2013-02-20 2016-05-19 バレリオン セラピューティクス， エルエルシー ポンぺ病の処置のための方法および組成物
JP2016523835A (ja) * 2013-05-15 2016-08-12 リージェンツ オブ ザ ユニバーシティ オブ ミネソタ 中枢神経系へのアデノ随伴ウイルスを介した遺伝子導入
JP6851964B2 (ja) 2014-09-30 2021-03-31 アミカス セラピューティックス インコーポレイテッド 炭水化物が増大している非常に強力な酸性アルファ−グルコシダーゼ
WO2016178431A1 (ja) * 2015-05-07 2016-11-10 国立大学法人 東京大学 ポリイオンコンプレックス型ポリマーソームを用いたナノリアクタとその製造方法
EP3344337A4 (en) * 2015-08-31 2019-03-06 Duke University METHOD AND COMPOSITIONS FOR TREATING CYTOPLASMATIC GLYCOGEN MEMORY DISEASES
US10940125B2 (en) 2015-09-18 2021-03-09 Duke University Methods and compositions for the treatment of steatosis-associated disorders
IL299470B2 (en) 2015-12-30 2026-05-01 Amicus Therapeutics Inc Improved acid alpha-glucosidase for the treatment of Pompe disease
KR102618519B1 (ko) 2016-03-30 2023-12-28 아미쿠스 세라퓨틱스, 인코포레이티드 재조합 산 알파-글루코시다제를 포함하는 제형
CA3019354A1 (en) 2016-03-30 2017-10-05 Amicus Therapeutics, Inc. Method for selection of high m6p recombinant proteins
US11253612B2 (en) 2016-04-15 2022-02-22 The Trustees Of The University Of Pennsylvania Gene therapy for treating mucopolysaccharidosis type II
CN119113091A (zh) 2017-05-15 2024-12-13 阿米库斯治疗学公司 重组人类酸性α-葡萄糖苷酶
EP3684938A1 (en) 2017-09-22 2020-07-29 The Trustees of the University of Pennsylvania Gene therapy for treating mucopolysaccharidosis type ii
WO2020163480A1 (en) * 2019-02-05 2020-08-13 Amicus Therapeutics, Inc. Recombinant human acid alpha-glucosidase and uses thereof
IT202300005733A1 (it) * 2023-03-27 2024-09-27 St Microelectronics Int Nv Circuito di comunicazione, sistema e procedimento corrispondenti

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3063911A (en) * 1961-04-03 1962-11-13 Taisho Pharmaceutical Co Ltd Acid-stable digestive enzyme preparation and process of making same
US5464778A (en) 1989-03-08 1995-11-07 Board Of Regents Of The University Of Oklahoma Glycoprotein ligand for P-selectin and methods of use thereof
US5356804A (en) * 1990-10-24 1994-10-18 Mount Sinai School Of Medicine Of The City Of New York Cloning and expression of biologically active human α-galactosidase A
US6118045A (en) 1995-08-02 2000-09-12 Pharming B.V. Lysosomal proteins produced in the milk of transgenic animals
WO1999058691A2 (en) 1998-05-13 1999-11-18 Harbor-Ucla Recombinant (alpha)-l-iduronidase, methods for producing and purifying the same and methods for treating diseases caused by deficiencies thereof
DK2020438T3 (en) 1998-12-07 2018-07-23 Genzyme Corp Treatment of Pompe disease
US6534300B1 (en) 1999-09-14 2003-03-18 Genzyme Glycobiology Research Institute, Inc. Methods for producing highly phosphorylated lysosomal hydrolases
US7056712B2 (en) * 2000-07-18 2006-06-06 Duke University Treatment of glycogen storage disease type II
US7629309B2 (en) 2002-05-29 2009-12-08 Zystor Therapeutics, Inc. Targeted therapeutic proteins
DE602005020745D1 (de) * 2004-02-10 2010-06-02 Zystor Therapeutics Inc Saure alpha-glukosidase und fragmente davon
US8470552B2 (en) 2009-10-12 2013-06-25 Keck Graduate Institute Strategy to reduce lactic acid production and control PH in animal cell culture

Also Published As

Publication number Publication date
PT1301201E (pt) 2007-03-30
CY1123084T1 (el) 2021-10-29
SI3108895T1 (sl) 2019-01-31
DE60126947D1 (de) 2007-04-12
US20120058132A1 (en) 2012-03-08
ES2799882T3 (es) 2020-12-22
AU2010200487A1 (en) 2010-03-04
EP3108895A1 (en) 2016-12-28
JP2016056206A (ja) 2016-04-21
JP2014185187A (ja) 2014-10-02
EP3449934A1 (en) 2019-03-06
EP3449934B1 (en) 2020-05-20
US7056712B2 (en) 2006-06-06
EP2767291A3 (en) 2014-10-08
DK2767291T3 (en) 2016-12-05
US20020110551A1 (en) 2002-08-15
JP5792774B2 (ja) 2015-10-14
DK3108895T3 (en) 2018-11-26
JP2013231081A (ja) 2013-11-14
ES2277931T3 (es) 2007-08-01
HK1054690A1 (en) 2003-12-12
US20180185457A1 (en) 2018-07-05
CA2416492C (en) 2008-04-29
LT3449934T (lt) 2020-08-10
EP3108895B1 (en) 2018-09-19
DE60126947T2 (de) 2007-10-31
DK3449934T3 (da) 2020-06-29
EP2767291A2 (en) 2014-08-20
DK1301201T3 (da) 2007-04-02
SI2767291T1 (sl) 2016-11-30
HK1197656A1 (en) 2015-02-06
JP2018199721A (ja) 2018-12-20
US20050123531A1 (en) 2005-06-09
JP2017137357A (ja) 2017-08-10
JP5113312B2 (ja) 2013-01-09
EP1301201A1 (en) 2003-04-16
AU7194101A (en) 2002-01-30
HK1103363A1 (en) 2007-12-21
AU2001271941B2 (en) 2007-03-01
JP6163216B2 (ja) 2017-07-12
US8900552B2 (en) 2014-12-02
US20150004152A1 (en) 2015-01-01
US20160184410A1 (en) 2016-06-30
CY1120977T1 (el) 2019-12-11
US20100254966A1 (en) 2010-10-07
SI3449934T1 (sl) 2020-09-30
EP1301201B1 (en) 2007-02-28
BR0113006A (pt) 2004-10-19
ES2523024T3 (es) 2014-11-20
US10792341B2 (en) 2020-10-06
PT3449934T (pt) 2020-06-25
JP2020019822A (ja) 2020-02-06
CA2416492A1 (en) 2002-01-24
DK1782825T3 (da) 2014-11-03
MXPA03000474A (es) 2003-10-06
US9370556B2 (en) 2016-06-21
PT2767291T (pt) 2016-10-25
US20210169996A1 (en) 2021-06-10
LT2767291T (lt) 2016-11-25
JP2018002749A (ja) 2018-01-11
JP2004503598A (ja) 2004-02-05
LT3108895T (lt) 2018-11-26
ES2700865T3 (es) 2019-02-19
US20130195834A1 (en) 2013-08-01
ATE355075T1 (de) 2006-03-15
TWI280882B (en) 2007-05-11
WO2002005841A1 (en) 2002-01-24
EP2767291B1 (en) 2016-09-14
PT1782825E (pt) 2014-11-04
US20080175833A1 (en) 2008-07-24
ES2599401T3 (es) 2017-02-01
JP2008081507A (ja) 2008-04-10
US9907839B2 (en) 2018-03-06
JP2012006953A (ja) 2012-01-12

Similar Documents

Publication Publication Date Title
CY1123084T1 (el) Θεραπεια των ασθενειων αποθηκευσης γλυκογονου τυπου ιι
IL173032A0 (en) Pyridazine derivatives and their use as therapeutic agents
SG146648A1 (en) Pharmaceutical compositions for treating premature ejaculation by pulmonary inhalation
GB0223038D0 (en) Therapeutic compounds
GB0225474D0 (en) Therapeutic agents
DE60126980D1 (de) Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen
TW200502385A (en) Modulation of forkhead box o1a expression
NZ516349A (en) Conjugates of phytosterol or phytostanol with ascorbic acid and use thereof in treating or preventing cardiovascular disease
ATE399782T1 (de) Zur behandlung von schmerzen geeignete phenylcarbonsäureamidverbindungen
IL162384A0 (en) Composition inhibiting matrix-metallproteinases for the treatment of neoplastic diseases
GB0211247D0 (en) Compositions and methods for treating or preventing convulsions or seizures
UA72927C2 (uk) Композиція для лікування печінково-клітинного раку, що містить доцетаксель
MXPA05014184A (es) Utilizacion de acido hialuronico para la preparacion de composiciones para el tratamiento de aftas en la cavidad oral.
DE60142899D1 (de) Verbindungen für den transfer von oligonukleotiden
MXPA06007007A (es) Derivados de prolina usados como ingredientes farmaceuticos activos para el tratamiento de tumores.
DE50100833D1 (de) Verwendung von 2-methyl-thiazolidin-2,4-dicarbonsäure und / oder ihrer physiologisch verträglichen salze zur herstellung eines medikaments zur behandlung von krebserkrankungen
ATE344662T1 (de) Mittel enthaltend n-chlortaurin sowie dessen verwendung zur behandlung von schleimhautpolypen
ATE548048T1 (de) Oncomodulin zur behandlung von neurologishen erkrankungen
WO2002076400A3 (en) Inosine compounds and their use for treating or preventing an inflamation or a reperfusion disease
WO2005089426A3 (en) Method of treating sepsis
WO2003080624A3 (en) Dithiolopyrrolone derivatives useful in the treatment of proliferative diseases
EP1782825A3 (en) Treatment of glycogen storage diseases type II
UA31369A (uk) Спосіб покращання кровотоку пілородуоденальної зони
TH48583A (th) สารผสมสำหรับชักนำการเจริญ
UA34199A (uk) Спосіб лікування пародонтиту